| 93.43 Data as of May 17 |  -0.13 / -0.14%Today’s Change | 80.09 Today|||52-Week Range 102.04 | +1.36% Year-to-Date |
| Shire Beats on EPS But GAAP Results Lag May 06 / MotleyFool.com |
| Previous close | 93.56 |
| Today’s open | 93.22 |
| Day’s range | 93.16 - 93.75 |
| Volume | 431,190 |
| Average volume (3 months) | 568,015 |
| Market cap | $17.3B |
| Dividend yield | 0.56% |
| Earnings growth (last year) | -14.55% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +9.50% |
| Revenue growth (last year) | +9.69% |
| P/E ratio | NM |
| Price/Sales | 3.64 |
| Price/Book | 4.60 |
| Today’s change | Today’s % change | |
|---|---|---|
| ZTSZoetis Inc | +0.51 | +1.53% |
| VRTXVertex Pharmaceutica... | +1.60 | +2.05% |
| ACTActavis Inc | +1.89 | +1.53% |
| ALXNAlexion Pharmaceutic... | +1.08 | +1.06% |
| Next reporting date | July 25, 2013 |
| EPS forecast (this quarter) | $1.64 |
| Annual revenue (last year) | $4.7B |
| Annual profit (last year) | $746.8M |
| Net profit margin | 15.92% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chief Executive Officer & Director Angus C. Russell, CA |
Chief Executive Officer-Designate & Director Flemming Ørnskov, MD, MBA |
Corporate headquarters Dublin, -- |
.
